Table 4 The correlation between TMOD1 and PTCSC2 polymorphisms and thyroid carcinoma susceptibility stratified by age and sex
SNP-ID | Model | Genotype | Age ≤ 45 | Age > 45 | Female | Male | ||||
|---|---|---|---|---|---|---|---|---|---|---|
OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |||
rs10982622 | Codominant | AG | 0.61 (0.41–0.90) | 0.014 | 0.87 (0.60–1.25) | 0.443 | 0.69 (0.50–0.94) | 0.019 | 0.89 (0.54–1.46) | 0.631 |
GG | 1.00 | 1.00 | 1.00 | 1.00 | ||||||
Dominant | AA.AG | 0.72 (0.50–1.04) | 0.084 | 0.86 (0.62–1.21) | 0.390 | 0.74 (0.55–0.99) | 0.043 | 0.94 (0.59–1.47) | 0.773 | |
GG | 1.00 | 1.00 | 1.00 | 1.00 | ||||||
rs925489 | Allele | T | 1.00 | 1.00 | 1.00 | 1.00 | ||||
C | 1.38 (0.90–2.11) | 0.143 | 1.51 (1.03–2.20) | 0.032 | 1.20 (0.85–1.68) | 0.306 | 2.17 (1.30–3.61) | 0.003 | ||
Codominant | CT | 1.33 (0.84–2.11) | 0.223 | 1.54 (1.01–2.35) | 0.044 | 1.13 (0.77–1.64) | 0.536 | 2.34 (1.33–4.06) | 0.003 | |
TT | 1.00 | 1.00 | 1.00 | 1.00 | ||||||
Dominant | CC.CT | 1.38 (0.88–2.19) | 0.164 | 1.57 (1.04–2.37) | 0.032 | 1.17 (0.81–1.69) | 0.407 | 2.39 (1.38–4.14) | 0.002 | |
TT | 1.00 | 1.00 | 1.00 | 1.00 | ||||||
Additive | / | 1.43 (0.91–2.22) | 0.119 | 1.54 (1.05–2.26) | 0.029 | 1.20 (0.85–1.69) | 0.305 | 2.39 (1.39–4.13) | 0.002 | |
rs965513 | Allele | G | 1.00 | 1.00 | 1.00 | 1.00 | ||||
A | 1.36 (0.88–2.09) | 0.165 | 1.44 (0.98–2.10) | 0.059 | 1.18 (0.84–1.66) | 0.347 | 2.02 (1.21–3.39) | 0.007 | ||
Codominant | AG | 1.31 (0.82–2.08) | 0.260 | 1.45 (0.96–2.21) | 0.083 | 1.11 (0.76–1.62) | 0.600 | 2.14 (1.23–3.74) | 0.007 | |
GG | 1.00 | 1.00 | 1.00 | 1.00 | ||||||
Dominant | AA.AG | 1.36 (0.86–2.16) | 0.193 | 1.48 (0.98–2.24) | 0.061 | 1.15 (0.79–1.67) | 0.460 | 2.19 (1.26–3.82) | 0.006 | |
GG | 1.00 | 1.00 | 1.00 | 1.00 | ||||||
Additive | / | 1.40 (0.89–2.20) | 0.141 | 1.46 (1.00-2.15) | 0.053 | 1.18 (0.84–1.67) | 0.346 | 2.20 (1.28–3.81) | 0.005 | |